Comments of Ghana on Zilpaterol Hydrochloride

(CX/EXEC 22/83/2 Add.2 of Agenda Item 2: Critical Review Part 3 (zilpaterol))

Agenda Item 4.8  Codex Committee on Residues of Veterinary Drugs in Food (CX/CAC 22/45/10)

Draft position on MRLS for zilpaterol hydrochloride (cattle fat, kidney, liver, muscle)

Position: Ghana commends the Codex Chair and Vice Chair for the informal consultations with all parties with the aim of reaching consensus on the matter of MRL for zilpaterol hydrochloride. Ghana supports a science-based and progressive approach to the resolution of the issue of zilpaterol and on the strength of JECFA evaluation, Ghana supports the final adoption of the MRLs for zilpaterol hydrochloride.

Rationale: Ghana recalls the scientific evaluations conducted by JECFA at its 78th (2013), 81st (2015) and 85th (2017) meetings on the issue of MRL for zilpaterol and the outcome that there were no public health concerns regarding the proposed MRL. This position was further upheld by other risk assessment bodies that have also concluded that overall, the approach followed by JECFA to establish MRLs for Zilpaterol hydrochloride appears to be scientifically sound. Ghana notes that this veterinary drug is already being used in international trade. Given that there is ongoing international trade with several Codex members having already established their national MRLs for zilpaterol, there is the need to harmonize these standards at the Codex level to ensure availability of an international reference for regulation at the national level. Without an international standard, each country would have to conduct its own scientific risk assessment when adopting its measures on zilpaterol. This is highly problematic for developing countries, as this is a costly and time-consuming process and could lead to different national standards, causing even more unnecessary trade barriers. Therefore, having Codex MRLs for zilpaterol is better than not having as it will be critical in the resolution of international trade disputes.